BNGO Jan 2025 2.000 put
| Previous Close | 1.1300 |
| Open | 1.0900 |
| Bid | 0.7800 |
| Ask | 1.7100 |
| Strike | 2.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 1.0900 - 1.1300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 484 |
- GlobeNewswire
Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is among several forms of Müllerian agenesis, a disorder impacting 1 in 4,500 females which is indicated by the absence or underdevelopment of the female reproductive systemResearchers in the study hypothesized that a genome-wide structural variant (SV) analysis would result in the identification of rare SVs relevant to MRKH’s genetic etiology, which might lead to better understanding of the syndrome and ultimately inform potential therapies and tre
- Motley Fool
Buy This Magnificent Growth Stock Before It's Too Late
Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.
- GlobeNewswire
Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis
SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. These LDTs offer a genome-wide assessment of structural variants (SVs) and provide comprehensive testing for most common and rare chromosomal abnormalities. OGM-DxTM Postnatal Whole Genome SV tests pe
